Partners
Founded in The Netherlands in 2020, TrueMass designs charge detection mass spectrometry (CDMS) instruments dedicated to the analysis of macromolecules. The TrueMass CDMS technology brings researchers a step closer to obtaining the true mass of previously unattainable large biomolecules, with the ultimate goal of accelerating scientific discovery and shortening time to market for new innovations, such as therapeutics and advanced materials. TrueMass is responsible for developing the Mass Analyser and Electrospray interface for this instrument.
Spectroswiss is a high-tech company based in Lausanne, Switzerland, specializing in advanced hardware and software solutions for Fourier Transform Mass Spectrometry (FTMS). Founded in 2014 as a spin-out from the Biomolecular Mass Spectrometry Laboratory at EPFL, we are committed to driving innovation in FTMS data acquisition, processing, and analysis.
Our FTMS Boosters provide access to true raw data (FTMS time-domain transients), delivering unmatched precision and depth in mass spectrometry research. Paired with our Peak-by-Peak software, researchers can achieve state-of-the-art data processing and analysis, unlocking the full potential of their FTMS instruments.
Beyond technology, we offer expert consulting, contract research (CRO) services, and specialized training, empowering academic and industrial scientists to optimize FTMS workflows. With our headquarters in Lausanne and a global presence, we support the scientific community with cutting-edge FTMS solutions that push the boundaries of mass spectrometry.
Fossiliontech will lead the development of an innovative Smart Spray Source aimed at advancing the analysis of viral particles in mass spectrometry. Building on our expertise in cutting-edge ionization technologies, we will focus on addressing key challenges related to stability, reliability, and operational efficiency. Our research will follow a structured two-phase approach: the initial phase will focus on designing and validating a functional prototype for early-stage integration, followed by a second phase dedicated to refining the system and delivering a pre-commercial version optimized for performance and scalability.
Coave Therapeutics proprietary AAV engineering Advanced vectors-ligand conjugates (AligaterTM) platform uses a rational design approach to conjugate functionalizing moieties to specific amino acids at the capsid surface. These ligands include small molecules, peptides, etc. which are covalently linked to AAVs to improve tissue spreading and cell transduction. Within the consortium, Coave Tx will bring its expertise on viral vector characterization as well as various samples to analysis.
IRIG, a major research institute within CEA’s Fundamental Research Division, brings together experts in physics, chemistry, biology, health, nanosciences, and cryotechnologies. With over 1,000 researchers working across multiple disciplines, IRIG thrives on collaboration, tackling key societal challenges through cutting-edge science. Supported by world-class research platforms and strong academic and industrial partnerships, the institute drives innovation, from fundamental discoveries to real-world applications.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly.